apollo
0
Written By Veda Maddala , M Pharmacy
Reviewed By Dr Aneela Siddabathuni , MPharma., PhD
Last Updated Nov 23, 2024 | 4:50 PM IST
Darbitop 25 Injection 0.42 ml is used to treat anaemia (low red blood cell count) in person with long-term serious (chronic) kidney disease and persons receiving chemotherapy for some types of cancer (except for bone marrow or blood cells' cancer). It helps to reverse anaemia and reduce the need for blood transfusion. It contains Darbepoetin alfa, which works by providing signals to the bone marrow to make more red blood cells. In chronic kidney disease, when the kidney fails to produce sufficient erythropoietin protein that aids in the formation of red blood cells, this medicine stimulates the production of this protein in the bone marrow. It may cause common side effects such as shortness of breath, cough, low blood pressure during dialysis, headache, body aches, diarrhoea, injection site pain and abdominal pain.
Read more
Prescription drug

Whats That

tooltip
Prescription drug
 Trailing icon
Consult Doctor

Manufacturer/Marketer

Alniche Life Sciences Pvt Ltd

Consume Type

PARENTERAL

Return Policy

Not Returnable

Expires on or after

Jan-27

for this medicine

About Darbitop 25 Injection 0.42 ml

Darbitop 25 Injection 0.42 ml belongs to the class of medication called 'blood-forming agent'  primarily used to treat anaemia (low red blood cell count) in person with long-term serious (chronic) kidney disease and persons receiving chemotherapy for some types of cancer (except for bone marrow or blood cells' cancer). Darbitop 25 Injection 0.42 ml helps to reverse anaemia and reduce the need for blood transfusion. Anaemia occurs when the body has a lower amount of red blood cells or haemoglobin. In chronic kidney disease, the kidney gets damaged and doesn't filter the blood, leading to anaemia.

Darbitop 25 Injection 0.42 ml contains a protein 'Darbepoetin alfa' which works by providing signals to the bone marrow to make more red blood cells. Darbitop 25 Injection 0.42 ml is a biologic response modifier and erythropoiesis-stimulating protein. In chronic kidney disease, when the kidney fails to produce sufficient 'erythropoietin protein' which aids in the formation of red blood cells, Darbitop 25 Injection 0.42 ml stimulates the production of this protein in the bone marrow. 

Darbitop 25 Injection 0.42 ml will be injected by the healthcare provider. Do not self-administer. The most common side effects of Darbitop 25 Injection 0.42 ml are shortness of breath,  cough, low blood pressure during dialysis, headache, body aches, diarrhoea, injection site pain and abdominal pain. Most of these sides effects of Darbitop 25 Injection 0.42 ml do not require medical attention and gradually resolve over time. However, if the side effects are persistent, reach out to your doctor.

If you have uncontrolled/untreated high blood pressure or red cell aplasia (a type of anaemia) due to darbepoetin alfa or epoetin alfa, please inform your doctor before taking Darbitop 25 Injection 0.42 ml to avoid any complications. Also, mention all the other medications you are taking to affect the way Darbitop 25 Injection 0.42 ml works. Inform your doctor immediately, if you feel weak, lightheaded, tired, or short of breath, or if your skin looks pale as it may be signs that the body has stopped responding to Darbitop 25 Injection 0.42 ml. 

Uses of Darbitop 25 Injection 0.42 ml

Treatment of Anaemia (in cancer and chronic kidney disease)

Medicinal Benefits

Darbitop 25 Injection 0.42 ml is a human-made form of naturally occurring erythropoiesis-stimulating protein or erythropoietin (a hormone produced by the kidney's specialized cells and is responsible for protecting red blood cells against destruction and also stimulates the cells of bone marrow to produce more amount of red blood cells). Deficiency of erythropoietin happens when a person is suffering from chronic kidney diseases, which in turn cause low red blood cells count causing anaemia.  This medicine is primarily indicated for treating anaemia (low red blood cell count) in persons with long-term serious (chronic) kidney disease and persons receiving chemotherapy for some types of cancer except for bone marrow or blood cells' cancer. Darbitop 25 Injection 0.42 ml contains a protein 'Darbepoetin alfa' which works by providing signals to the bone marrow to make more red blood cells. 

Directions for Use

Darbitop 25 Injection 0.42 ml will be administered by a healthcare professional; do not self-administer.

Storage

Store in a cool and dry place away from sunlight

Side Effects of Darbitop 25 Injection 0.42 ml

  • Shortness of breath
  • Cough
  • Hypotension (low blood pressure)
  • Headache
  • Body aches
  • Diarrhoea
  • Injection site pain 
  • Abdominal pain (stomach pain) 

 

Drug Warnings

Darbitop 25 Injection 0.42 ml can enhance the risk of serious heart problems including heart attack so tell your doctor immediately if you notice shortness of breath, sudden numbness or weakness, chest pain, or trouble speaking or understanding. This medicine may also shorten survival time in some people with certain types of cancer. Inform your doctor before taking Darbitop 25 Injection 0.42 ml if you have heart disease, high blood pressure, kidney disease, stroke, heart attack, blood clot, seizure, or latex allergy. Do not take Darbitop 25 Injection 0.42 ml if you are pregnant or breastfeeding unless prescribed by the doctor. Darbitop 25 Injection 0.42 ml may affect a person's ability to drive as it may cause convulsion during initial days of treatment, so a person taking Darbitop 25 Injection 0.42 ml should avoid driving or operating any machine. Darbitop 25 Injection 0.42 ml should not be given to children below 12 years of age, as safety and effectiveness have not been established. Avoid consuming alcohol along with Darbitop 25 Injection 0.42 ml as it could lead to increased dizziness and sleepiness. 

Drug Interactions

Drug-Drug Interactions: Darbitop 25 Injection 0.42 ml may have interaction with other chemotherapy drugs (thalidomide),  immunosuppressant medication (cyclosporine),  antihypertensive medicines (captopril). 

Drug-Food Interactions: Avoid alcohol consumption while taking Darbitop 25 Injection 0.42 ml as it might cause increased dizziness and sleepiness.

Drug-Disease Interactions: Darbitop 25 Injection 0.42 ml may have interactions with disease conditions such as seizures, hemodialysis, hypertension, and thrombotic events
 

Drug-Drug Interactions Checker List

  • THALIDOMIDE
  • CYCLOSPORINE
  • CAPTOPRIL

Habit Forming

No

Diet & Lifestyle Advise

  • Limit the consumption of fluids, salt, potassium, phosphorous, and other electrolytes.
  • Eat a low-protein diet, and get enough calories from the foods if you are losing weight.
  • Eat foods that are high in vitamin B12, iron, and folic acid can fulfil the deficiencies of happed in kidney disease.
  • Include a little number of healthy fats in your diet that give you enough energy to be active during the day; however, try to limit fats that make you fatty. Try to include olive oil, peanut oil, and corn oil into your diet.
  • Rest well, get plenty of sleep.
  • Avoid smoking and alcohol consumption.
  • Using essential oils for massages can help increase circulation.

Special Advise

  • Certain diagnostic tests like Complete blood count (CBC) can help check the count of red blood cells.
  • Have regular haemoglobin tests to check whether there is an improvement in the level of red blood cells after taking Darbitop 25 Injection 0.42 ml or not.

Disease/Condition Glossary

Anaemia: It occurs when the body has a lower amount of red blood cells or haemoglobin than normal haemoglobin (iron-rich the protein responsible for allowing red blood cells to carry more oxygen from the lungs to the rest of the body).  In chronic kidney disease, the kidney gets damaged and doesn't filter the blood, leading to anaemia. Symptoms of anaemia in chronic kidney disease include fatigue or tiredness, shortness of breath, ashen skin, weakness, body aches, chest pain, dizziness, fainting, fast or irregular heartbeat, headache, sleep problems, and trouble in concentrating. 

bannner image

Alcohol

Unsafe

Avoid consumption of alcohol while taking Darbitop 25 Injection 0.42 ml as it may increase dizziness and sleepiness.

bannner image

Pregnancy

Caution

Avoid taking Darbitop 25 Injection 0.42 ml if you are pregnant unless prescribed by a doctor as Darbitop 25 Injection 0.42 ml is a pregnancy category C drug. Please consult your doctor if you have any concerns regarding this, your doctor will prescribe only if the benefits outweigh the risks.

bannner image

Breast Feeding

Caution

Consult your doctor before taking Darbitop 25 Injection 0.42 ml; your doctor will decide whether Darbitop 25 Injection 0.42 ml can be taken by breastfeeding mothers or not.

bannner image

Driving

Unsafe

Darbitop 25 Injection 0.42 ml causes convulsions (seizures), especially during the initial months of treatment. So, it is better not to drive or operate machinery unless you are alert.

bannner image

Liver

Caution

Dose adjustment may be needed in patients with liver impairment. Please consult your doctor if you have a liver impairment or any concerns regarding this.

bannner image

Kidney

Caution

Dose adjustment may be needed in patients with kidney impairment. Please consult your doctor if you have kidney impairment or any concerns regarding this.

bannner image

Children

Caution

Darbitop 25 Injection 0.42 ml should not be given to children as the safety and efficacy have not been established.

Country of origin

India

Manufacturer/Marketer address

S-14, 1St Floor, Janta Market, Rajouri Garden, New Delhi, 110 027
Other Info - DAR0089

Author Details

Doctor imageWe provide you with authentic, trustworthy and relevant information

FAQs

Darbitop 25 Injection 0.42 ml is used to treat anaemia (low red blood cell count) in person with long-term serious (chronic) kidney disease and persons receiving chemotherapy for some types of cancer (except for bone marrow or blood cells' cancer). Darbitop 25 Injection 0.42 ml helps to reverse anaemia and reduce the need for blood transfusion.
It is suggested to store the Darbitop 25 Injection 0.42 ml in the refrigerator and protect it from light. However, a person should not freeze it.
It is advised to tell your doctor about your medical conditions like heart disease, high blood pressure, kidney disease, a stroke, heart attack, or blood clot, a seizure, a latex allergy to avoid any type of medical condition.
A person who is allergic to any chemical compound present in Darbitop 25 Injection 0.42 ml or have uncontrolled/untreated high blood pressure, or ever had pure red cell aplasia (a type of anaemia) caused by using darbepoetin alfa, or epoetin alfa is not allowed to take a name.
Consult your doctor before taking Darbitop 25 Injection 0.42 ml if you are pregnant or planning for pregnancy. Your doctor will prescribe Darbitop 25 Injection 0.42 ml only if the benefits outweigh the risks.
Darbitop 25 Injection 0.42 ml contains a protein "Darbepoetin alfa", which works by providing signals to the bone marrow to make more red blood cells. As in chronic kidney disease, the kidney gets damaged and doesn't filter the blood in the way it should be leading to anemia.
Darbitop 25 Injection 0.42 ml may cause side effects such as injection site pain, cough, low blood pressure, headache, diarrhoea, body pains, shortness of breath or stomach pain. If these side effects persist or worsen, please consult your doctor.
After beginning treatment with Darbitop 25 Injection 0.42 ml, it takes around 2 to 6 weeks for increase in haemoglobin level in blood.
Darbitop 25 Injection 0.42 ml is used only if anaemia is due to chronic (long term) kidney disease and chemotherapy for some types of cancer (except for bone marrow and blood cells).
Darbitop 25 Injection 0.42 ml may cause high blood pressure particularly in patients with long term kidney disease due to the rapid increase of red blood cells in the initial 3 months after starting Darbitop 25 Injection 0.42 ml.
Darbitop 25 Injection 0.42 ml is not used in the treatment of cancer. It is used in treatment of anemia (low levels of healthy red blood cells) in patients receiving chemotherapy for some types of cancer (except for bone marrow or blood cells cancer).
Darbitop 25 Injection 0.42 ml should be used with extreme caution as it can cause serious side effects and can even be life-threatening. The patient should follow doctor’s recommendations strictly.
If you have deficiencies of folic acid, vitamin B12 or iron, you may not respond to Darbitop 25 Injection 0.42 ml. It is important that you take measures to correct these deficiencies. Other reasons may be infections, bleeding, inflammation and bone marrow fibrosis. If you have any concerns, consult your doctor.
Darbitop 25 Injection 0.42 ml is usually not recommended for children as the safety and effectiveness were not established. However, if you have any concerns regarding the use of Darbitop 25 Injection 0.42 ml for children, please consult your doctor.

Disclaimer

While we strive to provide complete, accurate, and expert-reviewed content on our 'Platform', we make no warranties or representations and disclaim all responsibility and liability for the completeness, accuracy, or reliability of the aforementioned content. The content on our platform is for informative purposes only, and may not cover all clinical/non-clinical aspects. Reliance on any information and subsequent action or inaction is solely at the user's risk, and we do not assume any responsibility for the same. The content on the Platform should not be considered or used as a substitute for professional and qualified medical advice. Please consult your doctor for any query pertaining to medicines, tests and/or diseases, as we support, and do not replace the doctor-patient relationship.
icon image

Keep Refrigerated. Do not freeze.Prepaid payment required.

Add to Cart